

Aerocrine

Pressrelease
February 27, 2015

Change in number of shares and votes in Aerocrine, etc.

With reference to Chapter 4 Section 9 in the Swedish Financial Instruments Trading Act, it is hereby announced that as a result of the recent rights issue in Aerocrine AB (Nasdaq Stockholm: AERO), the number of shares and votes in Aerocrine has increased during February 2015 as specified in the table below.

	Number of shares and votes
<i>February 1, 2015</i>	<i>155,416,387</i>
<i>Increase</i>	<i>542,721,067</i>
February 27, 2015	698,137,454

It is further announced that Rolf Classon now has resumed his position as chairman of the Board of Directors, after being on sick leave since December 2014.

For further information, please contact:

Marshall Woodworth, CFO, +1 919 749 8748 or +46 709 695 219

About Aerocrine

Aerocrine AB is a medical products company focused on improved management and care of patients with inflammatory airway diseases such as Asthma. Within this sector, Aerocrine is the world leader. Aerocrine markets NIOX MIINO® and NIOX VERO®, which enables fast and reliable point-of-care measurement of airway inflammation. These products plays a critical role in more effective diagnosis, treatment and follow-up of patients affected with inflammatory airway diseases. Aerocrine is based in Sweden with subsidiaries in the US, Germany, Switzerland and the UK. Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007 (AERO-B.ST). For more information please visit www.aerocrine.com and www.niox.com.

Aerocrine is required to disclose the information provided herein pursuant to the Financial Instruments Trading Act.
The information was submitted for publication at 08:00 am on February 27, 2015.